Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
Akero Therapeutics has announced multiple presentations at the upcoming EASL Congress 2025 in Amsterdam, showcasing research on their drug efruxifermin for treating metabolic diseases. The company will present two oral presentations and one poster focusing on liver disease treatment.
The first oral presentation by Dr. Mazen Noureddin will discuss efruxifermin's impact on fibrosis improvement in patients with compensated cirrhosis due to MASH, based on a 96-week Phase 2b trial (SYMMETRY). The second oral presentation by Prof. Quentin M. Anstee will explore the alignment of non-invasive fibrosis biomarkers with AI-based qFibrosis histology in MASH trials.
Additionally, a poster presentation by Prof. Jörn M. Schattenberg will demonstrate how qFibrosis enables earlier detection of fibrosis response in efruxifermin-treated patients with F2-F3 MASH in the 96-week HARMONY study. All presentations will take place between May 7-10, 2025.
Akero Therapeutics ha annunciato diverse presentazioni al prossimo Congresso EASL 2025 ad Amsterdam, dove presenterà ricerche sul loro farmaco efruxifermin per il trattamento delle malattie metaboliche. L'azienda terrà due presentazioni orali e un poster focalizzati sul trattamento delle malattie epatiche.
La prima presentazione orale, a cura del Dr. Mazen Noureddin, illustrerà l'effetto di efruxifermin sul miglioramento della fibrosi in pazienti con cirrosi compensata causata da MASH, basandosi su uno studio di Fase 2b della durata di 96 settimane (SYMMETRY). La seconda presentazione orale, condotta dal Prof. Quentin M. Anstee, analizzerà la correlazione tra biomarcatori non invasivi della fibrosi e l'istologia qFibrosis basata su intelligenza artificiale negli studi su MASH.
Inoltre, un poster presentato dal Prof. Jörn M. Schattenberg dimostrerà come qFibrosis consenta una rilevazione precoce della risposta fibrotica nei pazienti trattati con efruxifermin affetti da MASH F2-F3, nello studio HARMONY della durata di 96 settimane. Tutte le presentazioni si terranno dal 7 al 10 maggio 2025.
Akero Therapeutics ha anunciado múltiples presentaciones en el próximo Congreso EASL 2025 en Ámsterdam, donde mostrará investigaciones sobre su medicamento efruxifermin para el tratamiento de enfermedades metabólicas. La compañía realizará dos presentaciones orales y un póster centrados en el tratamiento de enfermedades hepáticas.
La primera presentación oral, a cargo del Dr. Mazen Noureddin, abordará el impacto de efruxifermin en la mejora de la fibrosis en pacientes con cirrosis compensada debido a MASH, basándose en un ensayo de fase 2b de 96 semanas (SYMMETRY). La segunda presentación oral, presentada por el Prof. Quentin M. Anstee, explorará la concordancia entre biomarcadores no invasivos de fibrosis y la histología qFibrosis basada en inteligencia artificial en ensayos de MASH.
Además, un póster presentado por el Prof. Jörn M. Schattenberg mostrará cómo qFibrosis permite una detección más temprana de la respuesta a la fibrosis en pacientes tratados con efruxifermin con MASH F2-F3 en el estudio HARMONY de 96 semanas. Todas las presentaciones se llevarán a cabo entre el 7 y el 10 de mayo de 2025.
Akero Therapeutics는 다가오는 2025년 EASL 학회에서 대사 질환 치료를 위한 약물 에프룩시퍼민(efruxifermin)에 관한 연구를 발표할 예정입니다. 회사는 간 질환 치료에 중점을 둔 두 건의 구두 발표와 한 건의 포스터 발표를 진행합니다.
첫 번째 구두 발표는 Dr. Mazen Noureddin이 맡아, 96주간 진행된 2b상 임상시험(SYMMETRY)을 기반으로 MASH로 인한 보상성 간경변 환자에서 에프룩시퍼민이 섬유증 개선에 미치는 영향을 다룹니다. 두 번째 구두 발표는 Prof. Quentin M. Anstee가 MASH 임상에서 비침습적 섬유증 바이오마커와 AI 기반 qFibrosis 조직학의 일치성을 탐구합니다.
추가로 Prof. Jörn M. Schattenberg의 포스터 발표는 96주간 진행된 HARMONY 연구에서 F2-F3 단계 MASH 환자에게 에프룩시퍼민을 투여했을 때 qFibrosis가 섬유증 반응을 조기에 감지하는 방법을 보여줍니다. 모든 발표는 2025년 5월 7일부터 10일까지 진행됩니다.
Akero Therapeutics a annoncé plusieurs présentations lors du prochain Congrès EASL 2025 à Amsterdam, mettant en avant des recherches sur leur médicament efruxifermin destiné au traitement des maladies métaboliques. L'entreprise présentera deux communications orales et un poster axés sur le traitement des maladies du foie.
La première communication orale, présentée par le Dr Mazen Noureddin, portera sur l'impact d'efruxifermin sur l'amélioration de la fibrose chez des patients atteints de cirrhose compensée due à la MASH, basée sur un essai de phase 2b de 96 semaines (SYMMETRY). La deuxième communication orale, par le Prof. Quentin M. Anstee, explorera la corrélation entre les biomarqueurs non invasifs de fibrose et l'histologie qFibrosis basée sur l'IA dans les essais MASH.
De plus, un poster présenté par le Prof. Jörn M. Schattenberg démontrera comment qFibrosis permet une détection plus précoce de la réponse fibrotique chez les patients traités par efruxifermin atteints de MASH F2-F3 dans l'étude HARMONY de 96 semaines. Toutes les présentations auront lieu du 7 au 10 mai 2025.
Akero Therapeutics hat mehrere Präsentationen auf dem bevorstehenden EASL Kongress 2025 in Amsterdam angekündigt, bei denen Forschungsergebnisse zu ihrem Medikament efruxifermin zur Behandlung von Stoffwechselerkrankungen vorgestellt werden. Das Unternehmen wird zwei mündliche Präsentationen und ein Poster mit Schwerpunkt auf der Behandlung von Lebererkrankungen präsentieren.
Die erste mündliche Präsentation von Dr. Mazen Noureddin wird die Auswirkungen von Efruxifermin auf die Verbesserung der Fibrose bei Patienten mit kompensierter Zirrhose aufgrund von MASH auf Basis einer 96-wöchigen Phase-2b-Studie (SYMMETRY) behandeln. Die zweite mündliche Präsentation von Prof. Quentin M. Anstee wird die Übereinstimmung nicht-invasiver Fibrose-Biomarker mit der KI-basierten qFibrosis-Histologie in MASH-Studien untersuchen.
Zusätzlich wird ein Poster von Prof. Jörn M. Schattenberg zeigen, wie qFibrosis eine frühere Erkennung der Fibrosereaktion bei mit Efruxifermin behandelten Patienten mit F2-F3 MASH in der 96-wöchigen HARMONY-Studie ermöglicht. Alle Präsentationen finden vom 7. bis 10. Mai 2025 statt.
- Multiple high-profile presentations at EASL Congress 2025 demonstrate strong scientific interest in Efruxifermin
- 96-week long-term data from SYMMETRY trial showing fibrosis improvement in cirrhosis patients suggests drug efficacy
- AI-based qFibrosis analysis validates drug effectiveness through multiple measurement methods
- Early detection of fibrosis response in HARMONY study indicates potential faster treatment benefits
- None.
Insights
Akero's upcoming presentations at EASL showcase extended 96-week clinical data from multiple trials, signaling continued progress in their MASH treatment program.
Akero's upcoming presentations at EASL 2025 demonstrate continued momentum in their clinical development program for efruxifermin in MASH (Metabolic dysfunction-Associated SteatoHepatitis). The company will deliver two oral presentations and one poster presentation, highlighting data from their key clinical trials.
The first oral presentation will showcase 96-week results from the SYMMETRY Phase 2b trial examining efruxifermin in patients with compensated cirrhosis due to MASH. This represents extended follow-up data in a population with advanced liver disease, where effective treatments are urgently needed.
The second oral presentation focuses on the alignment between non-invasive fibrosis biomarkers and HistoIndex AI-based qFibrosis histology in the HARMONY trial. This addresses an important methodological challenge in MASH research - finding reliable alternatives to invasive liver biopsies.
The poster presentation will discuss how qFibrosis enables earlier detection of fibrosis response in efruxifermin-treated patients in the 96-week HARMONY study. The selection of Akero's work for multiple presentations, including two oral sessions, indicates scientific recognition of their research quality and clinical relevance.
These presentations collectively demonstrate Akero's continued clinical progress and their commitment to comprehensive evaluation of efruxifermin's effects on liver fibrosis, a critical endpoint in MASH treatment development.
Akero's EASL presentations highlight advanced fibrosis assessment methods and long-term data in cirrhotic MASH patients, addressing critical unmet medical needs.
The upcoming presentations by Akero at EASL 2025 address several critical aspects of MASH treatment development. The 96-week data from the SYMMETRY trial in patients with compensated cirrhosis is particularly significant. Cirrhotic MASH represents the most advanced non-alcoholic form of liver disease, where patients face substantially increased risks of clinical decompensation and mortality.
The scientific community's interest in Akero's research is evidenced by the selection of two presentations for oral delivery at EASL, one of the premier global liver disease conferences. This suggests the data being presented has scientific merit worthy of highlighted presentation.
The company's exploration of AI-based qFibrosis assessment represents an important advancement in MASH trial methodology. Conventional histological assessment of liver biopsies is subject to sampling variability and reader interpretation differences. The validation of more objective, quantitative methods could substantially improve the reliability of treatment effect measurement.
The poster on earlier detection of fibrosis response addresses another key challenge in MASH drug development - the ability to identify treatment responders efficiently. Fibrosis improvement is strongly associated with better long-term clinical outcomes in MASH, making reliable assessment methods crucial for both clinical trials and eventual clinical practice.
These presentations collectively demonstrate advancement in both the clinical evaluation of efruxifermin and in the methodological approaches to measuring treatment response in MASH.
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two oral presentations and an upcoming poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, 2025, in Amsterdam, the Netherlands.
Details for the presentations are as follows:
Oral presentation 1
Title: Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY)
Speaker: Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Date/Time: Friday, May 9, 2025, from 12:15 PM – 12:30 PM CET
Presentation ID: GS-012
Oral Session: General Session 2
Oral presentation 2
Title: Alignment of response assessed by non-invasive fibrosis biomarkers and HistoIndex AI-based qFibrosis histology in metabolic dysfunction associated steatohepatitis (MASH) clinical trials: a new roadmap for robust drug efficacy assessment demonstrated in the HARMONY trial
Speaker: Prof. Quentin M. Anstee, Ph.D., FRCP, Ruth & Lionel Jacobson Chair of Personalised Medicine, Dean of Research & Innovation in the Faculty of Medical Sciences, Newcastle University, UK
Date/Time: Saturday, May 10, 2025, from 10:30 – 10:45 CET
Presentation ID: OS-096
Oral Session: MASLD: Clinical and therapeutical aspects II
Poster presentation
Title: qFibrosis enables earlier detection of fibrosis response in Efruxifermin-treated patients with F2-F3 MASH in 96-week HARMONY study
Presenter: Jörn M. Schattenberg, M.D., Professor of Medicine, Director of the Department of Medicine, Saarland University Medical Center, University of Saarland
Date/Time: Saturday, May 10, 2025, from 8:30 – 16:00 CET
Presentation ID: TOP-458
Session: Poster - MASLD: Therapy
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
Deerfield Group
617.910.6217
Peg.rusconi@deerfieldgroup.com
FAQ
What will Akero Therapeutics (AKRO) present at EASL Congress 2025?
What are the key findings of AKRO's SYMMETRY trial presented at EASL 2025?
How does Efruxifermin affect fibrosis in MASH patients according to AKRO's HARMONY study?
When will AKRO present at EASL Congress 2025?
What non-invasive methods does AKRO use to assess Efruxifermin's effectiveness?
